G

Giant Biogene Holding Co Ltd
HKEX:2367

Watchlist Manager
Giant Biogene Holding Co Ltd
HKEX:2367
Watchlist
Price: 36.4 HKD -4.96% Market Closed
Market Cap: 39B HKD

Giant Biogene Holding Co Ltd
Total Liabilities & Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Giant Biogene Holding Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
Giant Biogene Holding Co Ltd
HKEX:2367
Total Liabilities & Equity
ÂĄ8B
CAGR 3-Years
1%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Hengan International Group Company Ltd
HKEX:1044
Total Liabilities & Equity
ÂĄ42.2B
CAGR 3-Years
-4%
CAGR 5-Years
-4%
CAGR 10-Years
2%
Proya Cosmetics Co Ltd
SSE:603605
Total Liabilities & Equity
ÂĄ8.6B
CAGR 3-Years
16%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Yunnan Botanee Bio-Technology Group Co Ltd
SZSE:300957
Total Liabilities & Equity
ÂĄ8.3B
CAGR 3-Years
13%
CAGR 5-Years
50%
CAGR 10-Years
N/A
By-health Co Ltd
SZSE:300146
Total Liabilities & Equity
ÂĄ14.3B
CAGR 3-Years
3%
CAGR 5-Years
11%
CAGR 10-Years
18%
S
Shanghai Chicmax Cosmetic Co Ltd
HKEX:2145
Total Liabilities & Equity
ÂĄ3.6B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Giant Biogene Holding Co Ltd
Glance View

Market Cap
39B HKD
Industry
Consumer products

In the bustling entrepreneurial landscape of China's Xi'an comes a formidable player in the skincare industry—Giant Biogene Holding Co Ltd. Founded in the early 2000s, the company quickly established itself as a pioneer in the biocosmetic field, underpinned by its commitment to leveraging cutting-edge biotechnologies. Positioned at the intersection of science and beauty, Giant Biogene concentrates on the research, production, and sale of bioactive skincare ingredients and products. These formulations, rich in proteins and polypeptides, target aspiring consumers eager to invest in beauty products that promise both efficacy and luxury. The company’s emphasis on integrating advanced bioengineering techniques with traditional Chinese medicinal practices has allowed it to carve out a distinct niche in the market, often emphasizing the scientific rigor and innovative spirit behind their product lines. Giant Biogene's revenue flows primarily from its comprehensive suite of skincare products, which are distributed through a variety of channels, including e-commerce platforms and retail partnerships. The company taps into the rising demand for premium anti-aging and skin-repair products in China's robust beauty market. This inclination towards advanced skincare solutions is largely fueled by an increasingly affluent middle class that places high value on personal care and appearance. The company further augments its revenue streams by developing proprietary formulas and licensing these innovative technologies to other skincare brands, thereby capitalizing on its formidable R&D capabilities. By maintaining a symbiotic relationship between its research endeavors and market strategy, Giant Biogene continues to thrive as a vanguard of scientific beauty solutions amid evolving consumer preferences.

Intrinsic Value
53.06 HKD
Undervaluation 31%
Intrinsic Value
Price
G

See Also

What is Giant Biogene Holding Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
8B CNY

Based on the financial report for Dec 31, 2024, Giant Biogene Holding Co Ltd's Total Liabilities & Equity amounts to 8B CNY.

What is Giant Biogene Holding Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
35%

Over the last year, the Total Liabilities & Equity growth was 62%. The average annual Total Liabilities & Equity growth rates for Giant Biogene Holding Co Ltd have been 1% over the past three years , 35% over the past five years .

Back to Top